Sunday 11 October 2026 Export all SBRA data to Excel Powerpack

Sabra Healthcare REIT, Inc.

SBRA Real Estate Reit Healthcare Facilities

Sabra Healthcare REIT, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $774.6 million, up 10.2% from fiscal 2024. In the quarter to June 2026, revenue grew 24.7%, EPS fell 135.7%, free cash flow fell 666.1% and total debt rose 5.91%, each against the same quarter a year earlier. Dividend growth for five consecutive years, revenue growth for three.

18.96 0.12 +0.64%

Follow SBRA

Alert me

Market cap: $4.8B
P/E: 72.9×
Fwd P/E: 27.3×
Dividend yield: 6.33%
F-score: 5/9
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 4.47

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	1	—	—	—	—	—	1	—

Insider Ownership 0.59%

Capital & Financial Ratios $m

Market Cap 4,810.00

Revenue 859.56

Net Income 65.23

Free Cash Flow (277.23)

Net Debt 2,387.82

Current Ratio 3.07

Debt/Equity 0.95

P/E ratio 72.92

Fwd P/E 27.30

P/S ratio 5.56

P/B ratio 1.74

Past 5Y EPS Growth (0.91%)

This Y EPS Growth (26.49%)

Next Y EPS Growth 62.74%

Next Y revenue growth 19.80%

Next 5Y EPS Growth 8.62%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 81.98%

10-year low 10-year high

P/S against its own 10 years 40.47%

10-year low 10-year high

P/B against its own 10 years 93.72%

10-year low 10-year high

EV/Sales against its own 10 years 6.76%

10-year low 10-year high

Dividends

Payout Ratio 4.62

Annual Dividend Rate 1.20

Annual Dividend Yield 6.33%

	total	individual payouts
2028	Powerpack
2027	Powerpack
2026	1.20	0.30 0.30 0.30
2025	1.20	0.30 0.30 0.30 0.30
2024	1.20	0.30 0.30 0.30 0.30
2023	1.20	0.30 0.30 0.30 0.30
2022	1.20	0.30 0.30 0.30 0.30
2021	1.20	0.30 0.30 0.30 0.30
2020	1.35	0.45 0.30 0.30 0.30
2019	1.80	0.45 0.45 0.45 0.45
2018	1.80	0.45 0.45 0.45 0.45
2017	2.16	0.42 0.43 0.36 0.36 0.59
2016	1.67	0.41 0.42 0.42 0.42

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	47	66	78	238
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	467	509	512	353

	2023	2024	2025	Q'26
Payables	137	118	119	115
ST’ Debt	—	—	—	—
Other	—	—	—	—
	137	118	119	115

Compound Annual Growth %

	10y	5y	3y
Sales	12.48%	5.29%	7.43%
Cash Flow	11.15%	(0.35%)	3.36%
Earnings	8.45%	2.37%	0.00%
Book Value	10.36%	(3.70%)	(2.60%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	222	236	—	—	—
’25	184	189	190	212	775
’24	167	176	178	182	703
’23	161	161	162	163	648
’22	163	156	141	165	625
’21	152	153	129	136	570
’20	149	154	143	152	599

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	98	86	—	—	—
’25	80	81	100	87	349
’24	53	80	98	80	311
’23	68	70	83	79	301
’22	63	77	108	68	316
’21	69	84	106	98	356
’20	75	94	97	89	355

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(10)	(124)	—	—	—
’25	65	22	(108)	(36)	(57)
’24	40	38	42	96	215
’23	161	69	137	18	385
’22	32	68	31	126	256
’21	32	45	105	133	315
’20	2	63	84	82	231

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.16	(0.10)	—	—	—
’25	0.17	0.27	0.09	0.11	0.64
’24	0.11	0.10	0.13	0.19	0.54
’23	(0.04)	0.09	(0.07)	0.07	0.06
’22	0.18	0.07	(0.22)	(0.37)	(0.34)
’21	0.16	(0.61)	0.05	(0.11)	(0.52)
’20	0.17	0.14	0.18	0.18	0.67

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	14.92	18.48	15.70	15.88	5.55	12.31	11.44	10.08	12.83	15.60	Analyst estimates 2026–2028 Powerpack
	High	26.40	29.10	23.83	24.95	22.55	19.02	16.60	14.82	20.03	19.97
People
People	Employees	14	61	31	34	38	42	42	48	50	58
	Revenue/emp, $m	18.61	6.69	20.11	19.46	15.75	13.56	14.88	13.49	14.06	13.36
Income, $m
Income, $m	Revenue	261	408	623	662	599	570	625	648	703	775
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	71	159	288	79	156	81	22	19	128	153
	EBT margin, %	27.35	38.95	46.13	11.97	26.02	14.16	3.47	2.88	18.22	19.81
	Net income	70	158	279	69	138	(113)	(78)	14	127	156
	Depreciation	68	114	191	182	177	179	188	183	170	187
Per share, $
Per share, $	Revenue	3.99	3.87	3.50	3.54	2.90	2.60	2.71	2.80	3.01	3.21
	Earnings	0.92	1.40	1.51	0.37	0.67	(0.52)	(0.34)	0.06	0.54	0.64
	Cash flow	2.69	1.29	2.02	1.99	1.72	1.63	1.37	1.30	1.33	1.44
	Capex	(0.87)	(2.62)	0.52	1.35	(0.60)	(0.19)	(0.26)	0.36	(0.41)	(1.68)
	Free cash flow	1.83	(1.33)	2.55	3.34	1.12	1.44	1.11	1.66	0.92	(0.24)
	Book value	15.56	32.54	18.25	18.64	16.53	15.43	13.23	12.12	11.74	11.70
	Shares, m	65	106	178	187	206	219	231	231	233	241
Valuation, ×
Valuation, ×	P/E	26.76	13.70	10.84	62.76	25.93	0.00	0.00	283.80	32.07	29.14
	P/S	6.17	4.94	4.71	6.04	5.98	5.21	4.66	5.07	5.75	5.90
	P/B	1.58	0.59	0.90	1.15	1.05	0.88	0.95	1.17	1.48	1.62
	EV/Sales	10.68	11.81	9.80	9.59	9.84	9.21	8.59	8.72	9.09	9.06
	EV/FCF	23.32	(34.25)	13.46	10.16	25.46	16.65	20.93	14.68	29.69	(122.74)
Cash, $m
Cash, $m	Operating cash flow	176	136	361	372	355	356	316	301	311	349
	Capex	(57)	(277)	93	252	(124)	(41)	(59)	84	(95)	(406)
	Free cash flow	119	(141)	454	625	231	315	256	385	215	(57)
Balance, $m
Balance, $m	Working capital	91	599	79	48	22	372	323	330	391	393
	Total debt	1,211	3,394	3,232	2,402	2,372	2,394	2,507	2,414	2,418	2,529
	Net debt	1,176	2,807	3,172	2,353	2,307	2,279	2,453	2,367	2,351	2,451
	Shareholders’ equity	1,016	3,437	3,255	3,488	3,409	3,380	3,056	2,803	2,741	2,824
Returns, %
Returns, %	ROA	2.54	3.19	3.93	1.08	2.30	(1.90)	(1.32)	0.25	2.37	2.88
	ROIC	3.77	1.96	2.97	2.33	2.75	2.22	1.60	2.50	2.93	3.04
	ROE	5.80	6.65	8.05	2.05	4.01	(3.34)	(2.41)	0.47	4.57	5.59

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
DOC Healthpeak Properties, Inc.	$13.1B	53.8×	71.3×	+11.12% (above 0%: growing)	+60.00% (above 0%: growing)	−30.47% (below 0%: shrinking)	56.83%	16.18%	Compare
AHR American Healthcare REIT, Inc.	$11.1B	74.7×	80.1×	+24.29% (above 0%: growing)	+166.67% (above 0%: growing)	+9.53% (above 0%: growing)	20.35%	6.29%	Compare
CTRE CareTrust REIT, Inc.	$8.5B	22.7×	25.4×	+43.46% (above 0%: growing)	+5.56% (above 0%: growing)	+88.99% (above 0%: growing)	98.66%	67.53%	Compare
HR Healthcare Realty Trust Incorporated	$5.9B	— (loss-making)	— (loss-making)	−5.26% (below 0%: shrinking)	n/m	−28.80% (below 0%: shrinking)	64.88%	13.83%	Compare
SBRA Sabra Healthcare REIT, Inc.	$4.8B	72.9×	27.3×	+24.70% (above 0%: growing)	n/m	−666.09% (below 0%: shrinking)	100.00%	(13.59%)
NHI National Health Investors, Inc.	$3.2B	18.7×	20.2×	+33.81% (above 0%: growing)	+45.57% (above 0%: growing)	+2,585.45% (above 0%: growing)	72.18%	41.09%	Compare
LTC LTC Properties, Inc.	$2.3B	15.5×	18.8×	+64.11% (above 0%: growing)	+72.73% (above 0%: growing)	−213.92% (below 0%: shrinking)	100.00%	31.24%	Compare
MPT Medical Properties Trust, Inc.	$1.9B	— (loss-making)	39.5×	+7.87% (above 0%: growing)	n/m	−15.15% (below 0%: shrinking)	95.68%	3.31%	Compare
DHC Diversified Healthcare Trust	$1.8B	— (loss-making)	8.4×	−4.53% (below 0%: shrinking)	n/m	−93.96% (below 0%: shrinking)	23.11%	(0.14%)	Compare
Median of peers	$4.5B	22.7×	25.4×	+17.70%	+60.00%	−21.97%	68.53%	15.01%

All 16 Reit Healthcare Facilities stocks →

Sabra Healthcare REIT, Inc. (SBRA) key facts

Strength: Sabra Healthcare REIT, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $774.6 million, up 10.2% from fiscal 2024.
Sabra Healthcare REIT, Inc. (SBRA) is a Reit Healthcare Facilities company in the Real Estate sector, listed on Nasdaq.
As of October 9, 2026, SBRA traded at $18.96, a market capitalization of $4.8 billion.
Sabra Healthcare REIT, Inc. pays an annual dividend of $1.20 per share, a yield of 6.33%.
Return on equity was 5.59% and debt-to-equity 0.95.
Its Piotroski F-score is 5 out of 9 for fiscal 2025.